Denka now owns 33.4 percent of PlexBio's shares. PlexBio will use the financing for operations and product development.
The company said that the Centers for Medicare and Medicaid Services wrongly suspended its Medicare reimbursement payments, causing financial distress.
The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.
Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
John McDonough announced he is moving into an executive chairman role and will step down as CEO. The firm has begun searching for a new CEO.
For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
The deal covers Curetis' Unyvero A50 instrument system and test cartridges, and builds on a separate distribution agreement the company recently signed.
The company attributed the revenue increase to strong performance by its Primerdesign molecular diagnostics and Lab21 protein diagnostics units.
Within the company's diagnostics segment, revenues for molecular assays in particular declined 21 percent year over year.
Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
The clearance marks the first time that the tests have been indicated to follow a new paradigm in which two enzyme immunoassay tests can be conducted concurrently or sequentially, the FDA said.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
With the firm seeing lower profitability in diagnostics, its CEO said it is focusing on improving earnings strength with the Atellica Solution IVD platform.
The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.
Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
NeuMoDx's tests are designed for central laboratory use and run on the company's fully automated NeuMoDx 96 or 288 real-time PCR systems.
Last year, the Oklahoma City-based firm raised $1.25 million in investment funding and acquired health management platform LupusCorner.
The firm said it has entered exclusive agreements for distribution of its products in Estonia, Greece, Ireland, Saudi Arabia, and South Africa.
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.
LabCorp Diagnostics was down 2.8 percent, while Covance Drug Development was up 8 percent. The firm narrowed its revenue and earnings guidance for the year.